Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. (Q50994209)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

title

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

main subject

liver cirrhosis

0 references

hepatocellular carcinoma

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Davide Festi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

author name string

E Accogli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

S Sottili

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

M Orsini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

A Salzetta

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

V Novelli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

A Cipolla

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

C Fabbri

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

A Pezzoli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

E Roda

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

publication date

1 February 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

page(s)

141-147

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus. The major etiology of hepatocellular carcinoma

21 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Primary hepatocellular carcinoma following non-A, non-B posttransfusion hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Hepatitis B and C viral infections in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Hepatitis B virus. New and evolving issues

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Risk factors for hepatocellular carcinoma in Italy. Male sex, hepatitis B virus, non-A non-B infection, and alcohol

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Hepatitis C virus infection is an additive risk factor for development of hepatocellular carcinoma in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Risk factors for hepatocellular carcinoma in Northern Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Assessment of some risk factors for hepatocellular carcinoma: a case control study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

A large-scale cohort study on risk factors for primary liver cancer, with special reference to the role of cigarette smoking

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

1 reference

7 January 2021

A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

A randomised controlled trial with human lymphoblastoid interferon vs no treatment in chronic hepatitis B virus infection. Preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Long-term response to interferon-alfa 2b re-treatment in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Hepatocellular carcinoma in Italian patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Hepatitis B virus integration site in hepatocellular carcinoma at chromosome 17;18 translocation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980022-5

7 January 2021

10.1016/S0168-8278(96)80022-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8907566%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

1 reference